A Global Real-World Evidence Study on the Long-term Effectiveness of ABBV-951 in Advanced Parkinson´s Disease in Routine Clinical Practice (ROSSINI: Real-world Outcomes With continuouS Subcutaneous Levodopa INfusIon)
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Foscarbidopa/Foslevodopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ROSSINI
- Sponsors AbbVie
Most Recent Events
- 13 Dec 2024 Planned End Date changed from 13 May 2029 to 1 May 2029.
- 13 Dec 2024 Planned primary completion date changed from 13 May 2029 to 1 May 2029.
- 26 Dec 2023 Planned primary completion date changed from 16 Feb 2028 to 13 May 2029.